STING1 and neoplasm: Preclinical studies have shown that pharmacological STING agonists—including synthetic cyclic dinucleotide (CDN) analogs, non-nucleotide small molecules, and nanoparticle-based delivery systems—synergize with synergize with PD-1/PD-L1 inhibition to induce strong and durable anti-tumor immunity in models of TNBC (4T1) [25].